A 65-year-old woman is evaluated in the clinic for HTN follow up. She has no symptoms of concern. She has impaired fasting glucose and never smoked cigarettes. Medications: Amlodipine 5 mg. Physical examination: BP 130/80, other vital signs are normal. BMI 26. Lab: Total cholesterol 270 (Normal <200), HDL 50 (Normal > 40), LDL 155 (Normal <130), Triglyceride 330 mg/dl (Normal <160). Estimated 10-year atherosclerotic cardiovascular disease is 12%. What is the most appropriate therapy for primary prevention?
سؤال مجاني 2 من 10 اليوم · اشترك وكمّل بدون حد
اعرض الإجابة
الإجابة والشرح
ادخل لحسابك عشان نحفظ إجاباتك ونوريك أخطاءك.
الإجابة: D. Rosuvastatin
She is 65 (within 40–75), has LDL 155 mg/dL (in the 70–189 range) and an estimated 10-year ASCVD risk of 12% (≥7.5%). That meets the indication for moderate- or high-intensity statin therapy, so a statin such as rosuvastatin is first-line for primary prevention. Ezetimibe and PCSK9 inhibitors (alirocumab) are add-on agents, not first-line. Metformin treats glucose, not lipids.
ليش كل خيار صح أو غلط
-
A
ليش غلط
PCSK9 inhibitors (alirocumab) are for familial hypercholesterolemia or established ASCVD when statins plus ezetimibe are insufficient, not first-line primary prevention.
✓ view-material.pdf · p. 24 -
B
ليش غلط
Ezetimibe is an add-on to statin therapy (or monotherapy if statin-intolerant), not the first-line choice.
✓ view-material.pdf · p. 24 -
D
ليش صح
Age 40-75 with an estimated 10-year ASCVD risk of at least 7.5% (here 12%) and LDL 70-189 mg/dL is an indication for a moderate- or high-intensity statin, e.g. rosuvastatin.
✓ Dr. Al-Ahmadi - Dyslipidemia and Aortic Dissection✅.pdf · p. 3
- المصدر
- Dr. Al-Ahmadi - Dyslipidemia and Aortic Dissection✅.pdf · p. 3
- المحاضرة
- Obesity & Lipids · Endocrinology · Module B
- ظهر في
- MED43 ♂ Quiz B · MED43 ♀ Compre · MED42 Compre B